Newsletter · 2026-08-28 · Ashutosh Agarwal

Eli Lilly Buys a Second Act While the Obesity Fight Moves to Pills - The Healthcare Pulse - Week of August 28, 2026

The Healthcare Pulse for the week of August 21 to 28, 2026. Podcast synthesis on Eli Lilly committing roughly 5.6 billion dollars to vaccines, infectious disease and mRNA while settling a Zyprexa case for 800 million, the industry race to turn weekly injections into daily pills, AI already grading cancer slides and scheduling nurses, and Medicare Advantage payment rates lagging medical cost growth.

The Healthcare Pulse

Week of August 28, 2026: Eli Lilly Buys a Second Act While the Obesity Fight Moves to Pills

This Week at a Glance

The most interesting healthcare stories this week did not come from earnings. They came from a courtroom, a guilty plea, an FDA approval, and a takeover offer, and the podcasts that cover healthcare investing spent their time untangling what those events actually mean for the companies involved.

A few threads ran through everything:

• Eli Lilly bought itself a "second act" in a single week, spending $3.8 billion on vaccine and infectious-disease companies and up to $1.8 billion on an mRNA cancer partnership, while quietly settling a decades-old marketing case for about $800 million and raising its full-year revenue forecast. One podcast host argued the acquisitions matter far more than the headline settlement.
• The obesity-drug fight is moving from injections to pills. A biotech CEO laid out, in plain terms, why the whole industry is racing to turn once-a-week shots into once-a-day tablets, and why that is so hard to pull off.
• Artificial intelligence in healthcare got two very concrete airings, one on how AI is already reading cancer slides, another on how a startup is using it to fix the brutal math of nurse staffing.
• In the broader market, drug approvals kept coming at a fast clip (Gilead, Johnson & Johnson, Merck, Revolution Medicines, Jazz all cleared new medicines), while health insurers stayed under a cloud as the government held next year's Medicare payment increases below the rate that medical costs are actually rising.

Below, the people, the debates, and the specific numbers behind each.

The People Driving the Conversation

The hosts of Telltales (August 23) on Eli Lilly's busy week. Telltales is a markets podcast produced entirely with AI-generated voices, its two "anchors," Ava Cabot and Marcus Graham, walk through a cash-flow-focused research memo each week. This issue they zeroed in on Lilly, which in seven days:

• agreed to plead guilty to one misdemeanor and pay roughly $800 million over how it once marketed the antipsychotic Zyprexa,
• announced deals to buy three vaccine and infectious-disease companies for $3.8 billion,
• put $50 million upfront into an mRNA cancer partnership with CureVac worth up to $1.8 billion, and
• raised full-year revenue guidance to $85–$87 billion.

Their take was that the market fixated on the wrong number. On the settlement:

The $800 million sits against $21 billion of trailing free cash flow in the memo. That's about two weeks of production.

And on what actually deserves attention:

The vaccine and infectious disease deals are the ones I'd actually underwrite, because that's Lilly buying a second act while GLP-1 is still paying for everything.

In plain English: Lilly's obesity and diabetes franchise is throwing off so much cash that a near-billion-dollar legal bill barely registers, and management is plowing that cash into new businesses so the company has something to sell after today's blockbusters fade.

Dinesh Patel, CEO of Protagonist Therapeutics (PTGX), on Schwab Network (August 21), on the shift to oral drugs. Patel's company designs peptides, small protein-like molecules, that can be taken as a pill instead of an injection. He framed the obesity market as the clearest example of where patients are voting with their feet:

With the advent of peptides in the obesity space… the two major peptides are now injectable peptides, but now [oral] Vagovie is also available as an oral peptide. And the massive shift towards oral peptides… is a clear indication of what is it that the patients would prefer, especially for this kind of chronic indications.

(He is referring to the arrival of an oral version of a leading weight-loss drug; the point is that for conditions people manage for life, a daily pill beats a weekly shot on convenience.) He was candid about why so few companies pull this off:

You want the potency and specificity and efficacy of a big antibody drug, even though your chemical entity is 100 times smaller in size… So essentially you want the best of both worlds. And that is where it becomes very challenging.

He also gave a useful gauge of how active the FDA has been: in a normal year the agency approves "about 40 to 50 drugs in total," and by his count it had already approved "about 33 agents" this year, a busy pace with months still to go. Patel named Lilly's triple-hormone shot retatrutide as the most effective injectable for weight loss on the market, and said Protagonist is chasing its own oral version to compete. (Worth remembering: this is a CEO talking about his own company, so treat the enthusiasm accordingly.)

Two oncologists on Oncology Decoded (August 21), on AI reading cancer. The hosts walked through how artificial intelligence is already embedded in prostate-cancer care, flagging suspicious scans, and grading tumor slides more consistently than tired human eyes. Two commercial tools came up by name: Artera AI, which reads the actual tissue-slide images, and Decipher, which analyzes the tumor's genes. Their enthusiasm came with a warning about "black box" tools whose reasoning no one can fully see:

It's a bit of a black box… You're putting these path slides into the machine. They're getting scanned in. And then maybe they're using things outside of Gleason score. We don't actually know what everything is being picked up.

Their bottom line for anyone worried AI will replace doctors: it won't, at least not here:

You're not going to lose your job anytime soon. And I actually think it's actually going to increase the job force.

A health-system startup founder on Advantaged: An Alloy Partners Podcast (August 21), on the economics of nurse staffing. The guest runs Swift Workforce AI, a company built inside the Wellstar hospital system to use AI for nurse scheduling. The numbers he cited explain why hospitals are willing to pay for this:

• Nurses are the single biggest chunk of a hospital's workforce, "somewhere at 30 plus percent," ranging from 27% to as high as 40%.
• Nurse turnover runs about 16% a year, and replacing one nurse costs on average about $61,100; replacing a nurse manager runs an estimated $80,000 to $90,000.

He was refreshingly blunt about where AI does and doesn't take jobs, arguing companies should say so up front:

If it's non-clinical in your use cases as a tool, do include a replacement of whoever was performing that workflow, identify it and put it out there. Because that part is already happening.

The Key Debates

Debate 1: When a drug giant settles a lawsuit and goes on a shopping spree in the same week, which one is the story?

• One side (the acquisitions matter): As the Telltales hosts argued, Lilly's $800 million settlement is trivial against its cash generation, "about two weeks of production," while the $3.8 billion of vaccine and infectious-disease deals represent Lilly building a genuinely new business for the years after its current obesity and diabetes drugs peak (Telltales, August 23).
• The other side (valuation still asks a lot): The same memo carries Lilly at 58 times its trailing free cash flow, a rich price that already assumes years of strong growth. A lot has to go right to justify it, and buying your way into a new category is not guaranteed to work.

Debate 2: Is Merck's post-Keytruda future de-risked or over-hyped? Merck jumped 3.2% on August 21 after a positive late-stage melanoma trial for intismeran, its personalized mRNA cancer vaccine partnered with Moderna, used alongside its mega-blockbuster Keytruda.

• Bull case: Analysts rushed to raise targets, calling the data a validation of the mRNA approach across more cancers: Goldman Sachs to $160 from $140, Argus to $170 from $145, and Wolfe Research to $180 from $155, arguing the pairing of Keytruda with intismeran can "insulate some of the erosion" when Keytruda loses patent protection in 2029.
• Bear case: RBC Capital Markets kept a more cautious "sector perform" rating and a $150 target, warning that "execution risks are underestimated at its current valuation" and that growth could stay "modest for several years" as Merck navigates life after Keytruda.

Debate 3: Have health insurers found a bottom, or is the pain still coming? The government set next year's Medicare Advantage payment increase at roughly 2.48%, below the rate at which medical costs are climbing, and insurers are responding by trimming benefits and pulling out of unprofitable markets (with Humana alone exiting areas covering an estimated 600,000 members).

• Bear case: Erste Group downgraded UnitedHealth to Hold from Buy on August 27, arguing revenue growth in 2026 and 2027 is "very low" and below the sector average, while the stock's price-to-earnings ratio is "significantly higher" than peers.
• Bull case: Other shops nudged their UnitedHealth targets higher over the week (Bernstein to $512, KeyBanc to $500, UBS to $490), and the company's core medical-cost ratio actually improved year-over-year, a sign the worst of the cost surge may be normalizing.

Debate 4: Will AI help clinicians or replace them? The clearest through-line across the AI-in-healthcare podcasts was cautious optimism. On the medical side (Oncology Decoded), the view is that AI removes drudgery and improves consistency but still needs a human to make the call. On the operations side (Advantaged), the founder was willing to admit AI genuinely does replace some back-office roles, and argued the honest move is to say so rather than pretend otherwise.

Hot Topics Under Debate

• Oral obesity drugs go global. Eli Lilly launched Foundayo (orforglipron), its once-daily weight-loss pill, in the UK, the first European country to get it, at roughly £100–£120 (about $136–$164) a month by private prescription. A pill is far easier to make and ship at scale than an injection, which is why the whole sector, from Lilly to Novo Nordisk to smaller players like Protagonist, is racing here.
• Does staying on a weight-loss drug save money? Lilly published a real-world study showing that adults over 55 who stayed on Zepbound had healthcare costs up to 15% lower at six months, widening to an estimated $607 per patient per month (about 38% lower) by twelve months, versus similar untreated adults, enough to more than cover the $195-a-month cost of Medicare's GLP-1 Bridge program from month 12. Notably, the stock still fell about 3.3% that day, a reminder that good data does not always move a richly valued stock.
• A takeover with a lesson about debt. The Telltales hosts contrasted two companies trading at the same ~12x free-cash-flow multiple: radiopharmaceutical maker Lantheus (LNTH), which agreed to be bought by Curium for $102.50 a share in cash plus contingent payments worth up to $12 more (roughly $8 billion total) just five days after the FDA approved its Alzheimer's brain-imaging agent, and cable operator Charter, drowning in debt. Their takeaway on why one got a buyer and the other has to be its own:

The multiple tells you what the market will pay for the cash flow. The leverage tells you who gets to decide what happens to it.

• A small-cap eye-care name delivering. Telltales also flagged Harrow (HROW), a stock they own, which posted second-quarter revenue of $71 million, up 60% from the prior quarter, and reiterated full-year guidance of $350–$365 million in revenue. The catch, in their words: the company is heavily indebted (10.5x free cash flow), so "60% sequential growth on a balance sheet that tight is a good problem, right up until it's the only problem."
• mRNA keeps proving itself beyond COVID. Science News Daily (August 22) noted the FDA approved Moderna's M-Flusiva, an mRNA flu vaccine that in a trial of adults 50 and older "reduced influenza cases more than a licensed comparator," with particularly strong results in the 50–64 group, described as "a step beyond COVID-19 toward broader infectious diseases, cancer immunotherapy, and rare genetic disorders."

Emerging Themes to Watch

• The "second act" scramble in big pharma. Lilly is the loudest example, but the pattern, cash-rich drugmakers using today's blockbuster profits to buy tomorrow's growth in vaccines, infectious disease, and mRNA, is one to track. The question investors will keep asking: are these smart bets on the future, or expensive admissions that the current pipeline won't be enough?
• Pills replacing shots. The oral-peptide theme that Protagonist's CEO described is bigger than obesity. If companies can reliably turn injected antibody drugs into pills for conditions like Crohn's, psoriasis, and asthma, it reshapes how (and how cheaply) chronic diseases get treated. The hard part, as he admitted, is the science.
• AI as hospital plumbing, not just diagnosis. The Swift Workforce example points to a quieter AI opportunity: not flashy diagnosis, but the unglamorous administrative work (scheduling, staffing, documentation) that eats clinicians' time and hospitals' budgets. With nurse turnover at 16% and replacement costs above $60,000 a head, the financial case writes itself.
• AI in cancer care is already commercial. Tools like Artera and Decipher are not hypotheticals, they are being used to make real treatment decisions today. The open question the oncologists raised is trust: how comfortable should doctors be acting on an AI whose reasoning is a "black box"?

Stocks on the Radar

Direction reflects the tone of this week's podcast and news commentary, not a recommendation.

Upcoming Catalysts (Next ~2 Weeks)

• August 28–31, European Society of Cardiology (ESC) Congress, Munich. A dense run of late-stage heart-drug results, several with direct stock stakes:
  • LIBREXIA-ACS, Bristol Myers Squibb (BMY) and Johnson & Johnson's blood-thinner milvexian, in more than 14,000 patients after a heart attack.
  • CARDIO-TTRansform (Aug 28), Ionis (IONS) and AstraZeneca's eplontersen for a heart-muscle disease.
  • ACACIA-HCM (Aug 28), Cytokinetics' (CYTK) aficamten in a form of thickened-heart-muscle disease; a competitive read against BMY's Camzyos.
  • LEVEL (Aug 29), Tenax Therapeutics' (TENX) oral drug for a type of heart failure.
• August 30, PharmaEssentia's BESREMi faces an FDA decision for essential thrombocythemia, a blood disorder (would be the first new therapy for it in over 20 years). Separately, Protagonist and Takeda's rasfertide decision is expected around the same time, per the company's CEO.
• September 1, Medtronic (MDT) reports fiscal first-quarter earnings (watch cardiovascular, diabetes, and its Hugo surgical robot); Zepp Health (ZEPP) also reports.
• September 16, FDA Pediatric Advisory Committee, including post-market safety reviews of certain Medtronic devices.
• Looking just past the window: September 23, an FDA advisory panel on GRAIL/Illumina's Galleri multi-cancer blood test.

The Bottom Line

This was a week that rewarded reading past the headline. Eli Lilly's $800 million legal settlement led the news, but the more important move was the roughly $5.6 billion it committed to vaccines, infectious disease, and mRNA, a bet on what the company sells a decade from now. Merck's melanoma data lit up price targets, but the real argument is whether it does enough to offset the 2029 patent cliff on Keytruda. And a small radiopharmaceutical company's buyout became a lesson in why balance sheets, not just growth rates, decide who controls a company's fate.

Two structural stories kept surfacing across the podcasts: the drive to turn injected medicines into pills (with obesity leading the way), and the steady creep of AI into both the exam room and the back office of American healthcare. Meanwhile, the drug-approval machine keeps humming, five notable clearances this week alone, even as health insurers absorb the squeeze of government payment rates that aren't keeping up with costs.

For investors, the near-term calendar is dominated by heart-drug data out of the Munich cardiology meeting and a cluster of FDA decisions. But the bigger takeaway is thematic: the companies generating the most conversation are the ones spending today's profits to buy tomorrow's growth, and the market is still deciding how much to pay for that ambition.